You are here

Final Approval for Pergolide Announced

MIAMI – September 4, 2003 – IVAX Corporation (AMEX: IVX, LSE: IVX.L) announced today that it has received final approval for its Abbreviated New Drug Application (ANDA) for pergolide mesylate tablets in .05 mg, .25 mg and 1 mg dosage strengths and has begun marketing these tablets through the company’s wholly owned subsidiary, IVAX Pharmaceuticals, Inc.

Pergolide mesylate is the generic equivalent of Permax® tablets marketed by Amarin Corporation PLC for use as an adjunctive treatment in connection with Parkinson’s disease. U.S. sales of Permax during 2002 were approximately $50 million. Pergolide mesylate tablets’ active pharmaceutical ingredient is produced at IVAX’ facility in the Czech Republic, which will also be manufacturing the tablets.

Source: IVAX Corporation

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs